Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: A study using the U.K. and Germany mediplus databases

Pain Practice

Volumn 8, Issue 4, 2008, Pages 253-262

  Gore, Mugdha ^a,e   Sadosky, Alesia ^b,e   Leslie, Douglas ^c,e   Sheehan, Amy Heck ^d,e  

^a Avalon Health Solutions Inc   (United States)

^b PFIZER INC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PURDUE UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cytochrome P450; Diabetes; Diabetic neuropathy; Drug drug interactions; Mediplus database; Metabolic pathways; Neuropathic pain medications

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMITRIPTYLINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BISOPROLOL; CARBAMAZEPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DULOXETINE; ENALAPRIL; FENTANYL; FUROSEMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; HYDROCODONE; LEVOTHYROXINE; LISINOPRIL; METFORMIN; METHADONE; METOPROLOL; NORTRIPTYLINE; OXYCODONE; PAROXETINE; RAMIPRIL; SIMVASTATIN; UNINDEXED DRUG;

ADULT; AGED; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SURVEILLANCE PROGRAM; DRUG USE; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; GERMANY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MOOD DISORDER; NEUROPATHIC PAIN; PRESCRIPTION; SLEEP DISORDER; TREATMENT DURATION; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANALGESICS; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 48249129118     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00211.x     Document Type: Article

References (48)

1. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998; 91: 733-737.
2. Gore M, Brandenburg N, Dukes E, Hoffman D, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005; 30: 374-385.
3. Gore M, Brandenburg N, Hoffman D, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy (DPN): The patients' perspective. J Pain. 2006; 7: 892-900.
4. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: A controlled comparison of people with and without diabetes. Diabet Med. 2004; 21: 976-982.
5. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: A cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006; 20: 26-33.
6. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2005; 22: 681-685.
7. Dworkin RH, Backonja M, Rowbotham MC, etal. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60: 1524-1534.
8. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: Treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004; 63: 959-965.
9. Finnerup N, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118: 289-305.
10. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clin Proc. 2006; 81: S12-S25.
11. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006; 13: 1153-1169.
12. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007; 12: 13-21.
13. Dworkin RH, O'Connor PW, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007; 132: 237-251.
14. Lyrica® [pregabalin] capsules prescribing information. Pfizer, Inc., New York, NY. June 2007.
15. Cymbalta® [duloxetine] Capsules prescribing information. Eli Lilly and Company. Indianapolis, IN. May 2007.
16. Mann HJ. Drug-associated disease: Cytochrome P450 interactions. Crit Care Clin. 2006; 22: 329-345.
17. Manzi SF, Shannon M. Drug interactions-a review. Clin Pediatr Emerg Med. 2005; 6: 93-102.
18. Food and Drug Administration. Guidance for Industry. In vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Available at: http://www.fda.gov/cder/guidance/2635fnl.pdf. (Accessed January 20, 2008).
19. Ozminkowski RJ, Hylan TR, Melfi CA, et al. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Clin Ther. 1998; 20: 780-796.
20. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003; 289: 1652-1658.
21. Luisi AF, Owens NJ, Hume AL. Drugs and the elderly. In: Gallo JJ, Reichel W, eds. Reichels's Care of the Elderly: Clinical Aspects of Aging. Philadelphia, PA: Williams & Wilkins; 1999: 59-87.
22. Neurontin® [gabapentin] capsules prescribing information. Pfizer, Inc., New York, NY. March 2006.
23. Lamictal® [lamotrigine] capsules prescribing information. GlaxoSmithKline. Research Triangle Park, NC. August 2005.
24. Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician. 2000; 61: 1745-1754.
25. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. Lancet Neurol. 2003; 2: 473-481.
26. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006; 2: 137-146.
27. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs. 2003; 63: 17-32.
28. Elavil® [amitriptyline hydrochloride] capsules prescribing information. AstraZeneca Pharmaceuticals LP. Wilmington, DE. February 2003.
29. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: An update. Drug Saf. 2005; 28: 601-631.
30. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000; 356: 1667-1671.
31. Gore M, Dukes E, Rowbotham D, Tai K-S, Leslie DL. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract. 2006; 6: 265-272.
32. Lexi-Comp Online [Internet Database]. Lexi-Comp Inc. Available at: http://www.crlonline.com/crlsql/servlet/crlonline (Accessed October 2006).
33. Hansten PD. Drug interaction management. Pharmacy World and Science, 25, 94-97. Pharm World Sci. 2003; 25: 94-97.
34. DRUGDEX® System [Internet database] Version 5.1. Thomson Micromedex. Available at: http://www.micromedex.com (Accessed October 2006).
35. Amaryl® [glimepiride] capsules prescribing information. Sanofi-Aventis, Bridgewater, NJ. February 2006.
36. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997; 25: 1191-1199.
37. Zocor® [simvastatin hydrochloride] tablets prescribing information. Merck & Company, Whitehouse Station, NJ. May 2007.
38. Lipitor®[atorvastatin calcium]tablets prescribing information. Parke-Davis Division of Pfizer Inc. New York, NY. Novermber 2007.
39. Altace®[ramipril]capsules prescribing information. Monarch Pharmaceuticals, Bristol, TN. August 2007.
40. Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998; 63: 1097-1108.
41. Aprinox®[bendroflumethiazide]tablets prescribing information. Sovereign Medical, Basildon, Essex, UK. September 2005.
42. Tegretol®[carbamazepine]capsules prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. September 2006.
43. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology. 2004; 63 (suppl 4): S3-S8.
44. Ferrari A, Coccia CP, Bertolini A, Sternieri E, Methadone-metabolism, pharmacokinetics, and interactions. Pharmacol Res. 2004; 50: 551-559.
45. Ultram®[tramadol hydrochloride]capsules prescribing information. Ortho-McNeil Pharmaceuticals, Raritan, NJ. February 2007.
46. Effexor®[venlafaxine]capsules prescribing information. Wyeth Pharmaceuticals Inc. Philadelphia, PA. November 2007.
47. Paxil®[paroxetine hydrochloride]capsules prescribing information. GlaxoSmithKline. Research Triangle Park, NC. July 2006.
48. Celexa®[citalopram hydrobromide]capsules prescribing information. Forest Pharmaceuticals, Inc. St. Louis, MO. July 2007.